Dyadic International, Inc. is a biotechnology company headquartered in Jupiter, Florida, that specializes in the development and licensing of its proprietary C1 fungal expression platform. The C1 system leverages the filamentous fungus Myceliophthora thermophila to produce high-value proteins, enzymes, and biologics more efficiently than traditional bacterial, yeast or mammalian cell systems. Dyadic’s platform is designed to deliver scalable, cost-effective manufacturing solutions for pharmaceutical, industrial and agricultural applications.
Central to Dyadic’s business is the C1 expression technology, which has demonstrated the ability to generate rapid protein yields with simplified downstream processing. The platform has been employed to produce vaccine antigens, monoclonal antibody fragments, industrial enzymes and other specialized proteins. Through collaborative partnerships and license agreements, Dyadic provides access to its technology for companies seeking to accelerate product development while reducing production timelines and capital expenditure.
Founded in 1984, Dyadic has evolved from a research-focused organization into a commercial-stage enterprise with a global reach. The company has established research collaborations across North America, Europe and Asia, working with major pharmaceutical and biotechnology firms to validate the performance of its C1 system in diverse applications. Over the years, Dyadic has continually optimized its expression host and fermentation processes to meet regulatory requirements and commercial manufacturing standards.
Dyadic is led by a management team with extensive experience in commercial biotechnology and industrial enzyme markets. Under the leadership of its CEO, William “BJ” McGrath, the company has pursued strategic licensing deals and research collaborations that broaden the application of the C1 platform. As Dyadic advances its pipeline and expands its partner network, it remains focused on delivering sustainable, high-yield protein production solutions for the global life sciences industry.
AI Generated. May Contain Errors.
Free DYAI Stock Alerts